CASE REPORT

Ovarian cancer with the metastatic deposit in the cervix as rare case: a case report and literature review

Hasanuddin Hasanuddin , Sarjani Sarjani

Hasanuddin Hasanuddin
Oncology Division of Obstetrics and Gynecology Department, Faculty of Medicine, Universitas Syiah Kuala/dr. Zainoel Abidin General Hospital, Banda Aceh, Indonesia. Email: hasan.spog@yahoo.co.id

Sarjani Sarjani
Oncology Division of Obstetrics and Gynecology Department, Faculty of Medicine, Universitas Syiah Kuala/dr. Zainoel Abidin General Hospital, Banda Aceh, Indonesia
Online First: July 08, 2021 | Cite this Article
Hasanuddin, H., Sarjani, S. 2021. Ovarian cancer with the metastatic deposit in the cervix as rare case: a case report and literature review. Bali Medical Journal 10(2): 567-571. DOI:10.15562/bmj.v10i2.2417


Introduction: Although ovarian cancer incidence is lower than the cases of cancer of the uterine cervix and endometrial, the incidence of ovarian cancer is high. The mortality rate is highest among all gynecological malignancies. The patients often come for treatment at an advanced stage that has spread to the pelvis, especially to the organs such as the uterus, fallopian tubes, ovaries, and sigmoid colon through the passive spread and different hematogenous routes. This study aimed to review malignant disease in gynecologic oncology, supporting examinations and management.

Case Report: A woman, 52 years old, presented with abdominal pain one month before entering the hospital. She complained about difficulty urinating, not having a smooth bowel movement. From ultrasound examination showed an intra-abdominal mass measuring 14.3 cm x 11.2 cm x 11.1 cm, and the origin of the mass remains unclear. From contrast, pelvic CT scan showed a solid mass had spread to the uterine cervix, vagina and spread to the uterine body, infiltrated to the bladder, attached to the rectum part without intestinal obstruction, with a mass size of 7.7 cm x 7.1 cm x 16.6 cm. The procedure for this patient was an abdominal hysterectomy of total and salpingo-oophorectomy of both ovaries. The histopathology result was serious ovary adenocarcinoma.

Conclusion: The spreading of ovarian cancer is a mechanism that involves the interaction of many things, such as cancer cells from the primary tumor, which spread to the peritoneal cavity or spread hematogenously or lymphatically and enter the omentum. In this case, we had metastasis of ovarian cancer with cervical adhesions and a suspected mass in the sigmoid colon on intraoperative findings. With increasing knowledge about ovarian cancer, ovarian cancer pathogenesis, and metastases can be found and developed to treat disease and prevent spread.

 

References

Yeung TL, Leung CS, Yip KP, Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: Cell and molecular processes in cancer metastasis. Am J Physiol-Cell Physiol. 2015; 309: C444–C456. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26224579.

Sari NN, Prasista S, Suryantari SA, Darmawan IP, Satyarsa AB, Budiana IN. General Profile of Ovarian Cancer Patients in Sanglah General Hospital, Bali From January 2016 To December 2017. Int J Gynecol Cancer. 2018; 28: 836-836.

Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053-64. Available from: https://doi.org/10.2353/ajpath.2010.100105.

Manasa P, Sidhanth C, Krishnapriya S, Vasudevan S, Ganesan TS. Oncogenes in high grade serous adenocarcinoma of the ovary. Genes & Cancer. 2020;11(3-4):122. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33488950

Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC. Cell origins of high-grade serous ovarian cancer. Cancers. 2018;10(11):433. Available from: https://doi.org/10.3390/cancers10110433

Linus-Lojikip S, Subramaniam V, Lim WY, Amar-Singh HS. Survival of patients with advanced and recurrent ovarian cancer treated using integrative medicine in Malaysia: a case series. Complement Ther Clin Pract. 2019;37:73-85. Available from: https://doi.org/10.1016/j.ctcp.2019.09.001

Forstner R, Meissnitzer M, Cunha TM. Update on imaging of ovarian cancer. Curr Radiol Rep. 2016;4(6):1-11. Available from: https://doi.org/10.1007/s40134-016-0157-9

Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med-Us. 2019;8(16):7018-31. Available from: https://doi.org/10.1002/cam4.2560

Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010;2010:1-13. Available from: https://doi.org/10.1155/2010/932371

Budiana IN, Angelina M, Pemayun TG. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turkish-German Gynecol Assoc. 2019;20(1):47-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30362670.

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. The Lancet. 2014;384(9951):1376-88. Available from: https://doi.org/10.1016/S0140-6736(13)62146-7

Jacome LS, Deshmukh SK, Thulasiraman P, Holliday NP, Singh S. Impact of COVID-19 Pandemic on Ovarian Cancer Management: Adjusting to the New Normal. Cancer Management and Research. 2021;13:359-66. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33469377

Marth C, Reimer D, Zeimet AG. Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Ann Oncol. 2017;28:viii36-9. Available from: https://doi.org/10.1093/annonc/mdx450

Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203. Available from: https://doi.org/10.3322/caac.20113

Bookman MA. Optimal primary therapy of ovarian cancer. Ann Oncol. 2016;27:i58-62. Available from: https://doi.org/10.1093/annonc/mdw088

Saed GM, Morris RT, Fletcher NM. New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress. Ovarian Cancer: From Pathogenesis to Treatment. 2018:83-110. Available from: https://doi.org/10.5772/intechopen.73860


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0